<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963208</url>
  </required_header>
  <id_info>
    <org_study_id>1042-0603</org_study_id>
    <nct_id>NCT01963208</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension</brief_title>
  <official_title>A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone -
      on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic
      medications (AEDs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-cohort study comprised of 2 phases in each cohort. Phase 1 is a double-blind
      phase followed by Phase 2, an open-label phase. Cohort 1 will provide tolerability, safety,
      and PK information for ganaxolone 1200mg/d, 1800mg/d and placebo. Cohort 2 will investigate
      the efficacy, tolerability and safety of ganaxolone 1800mg/d compared to placebo. Cohort 1
      (N= approximately 50) will enroll into a 67-week study comprised of a 4-week prospective
      baseline period plus 4 week retrospective baseline followed by two treatment phases: a
      9-week randomized DB placebo-controlled treatment phase followed by a 52-week open label
      (OL) treatment phase. Cohort 2 (N=150) will enroll into a 72-week study comprised of a
      4-week prospective baseline period plus 4 week retrospective baseline followed by two
      treatment phases: a 14-week randomized DB placebo-controlled treatment phase followed by a
      52-week open label (OL) treatment phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage change in seizure frequency per 28 days in the double blind period relative to baseline</measure>
    <time_frame>14 wks (cohort 2)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in seizure frequency per 28 days</measure>
    <time_frame>9 wks (Cohort 1), 14 wks (Cohort 2) and 52 weeks (both)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders experiencing a ≥50% reduction from baseline to the end of the period, in total partial seizure frequency per 28 days</measure>
    <time_frame>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of seizure free subjects</measure>
    <time_frame>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of change</measure>
    <time_frame>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of change</measure>
    <time_frame>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of seizure-free days</measure>
    <time_frame>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Drug Resistant Partial Onset Seizure</condition>
  <arm_group>
    <arm_group_label>ganaxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, non-active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganaxolone</intervention_name>
    <description>200 mg and 225 mg capsules 2x/day</description>
    <arm_group_label>ganaxolone</arm_group_label>
    <other_name>gnx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>pbo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give informed consent in writing, or have a legally authorized representative
             able to do so

          -  Willing to enter and participate for the full term of the double blind phase and
             willing to enter into the open-label phase

          -  Male or female outpatients &gt; 18 years of age

          -  Have a confident diagnosis of drug-resistant epilepsy with partial-onset seizures
             (POS), with or without secondary generalization, for ≥2 years. Have residual POS
             despite having been treated in the past with at least 2 approved anti-epilepsy drugs
             (AEDs) either alone or in combination

          -  Based on history, subjects would be anticipated to have at least 3 POS during each
             4-week Baseline period and unlikely to have 21 or more consecutive POS-free days

          -  Currently being treated and maintained with a stable regimen of 1, 2, or 3 AEDs

          -  Able and willing to maintain daily seizure calendar

          -  Able and willing to take drug with food twice daily

          -  Sexually active women of childbearing potential must use acceptable birth control and
             have a negative pregnancy test at all visits

        Exclusion Criteria:

          -  Have had previous exposure to ganaxolone

          -  Known sensitivity or allergy to any component in the study drug, progesterone, or
             other related steroid compounds

          -  Exposure to any investigational drug or device &lt; 30 days prior to screening, or plans
             to take another investigational drug at any time during the study

          -  Time of onset of epilepsy treatment &lt; 2 years prior to enrollment

          -  Have generalized epilepsy, such as Lennox-Gastaut syndrome, juvenile myoclonic
             epilepsy, absence epilepsy, or non-epileptic seizures within the last 12- month
             period prior to study entry

          -  Have less than 3 POS seizures in a 28-day period or more than 21 consecutive
             seizure-free days during the Baseline period

          -  Have only simple partial seizures without any observable motor component

          -  Have innumerable seizures or status epilepticus within the last 12-months prior to
             screening

          -  Have more than 100 POS per 4-week Baseline period

          -  Have seizures secondary to illicit drug or alcohol use, infection, neoplasm,
             demyelinating disease, degenerative neurological disease, or central nervous system
             (CNS) disease deemed progressive, metabolic illness, or progressive degenerative
             disease

          -  Current use of vigabatrin is not permitted. If prior use of vigabatrin, must have
             documented stable visual fields

          -  Current use of ezogabine is not permitted. If prior use, must have been off the
             medication for at least 3 months prior to screening and have had documented normal
             fundoscopic exam by ophthalmologist

          -  Are planning surgery, or to be evaluated for surgery, during the double blind phase
             to control seizures including VNS implantation

          -  Are suffering from acute or progressive neurological disease, moderate or severe
             psychiatric disease, or severe mental abnormalities that are likely to require
             changes in drug therapy during the double blind portion of the study or interfere
             with the objectives of the study or the ability to adhere to the protocol
             requirements

          -  Have a history of an actual suicide attempt in the last 5 years or more than 1
             lifetime suicide attempt

          -  Have a positive urine drug screen at Screening or meet criteria for current or
             historical Substance Use Disorder (DSM-V criteria) within the past 5 years.

          -  Have any medical condition that, in the investigator's judgment, is considered to be
             clinically significant and could potentially affect subject safety or study outcome,
             including but not limited to: clinically significant cardiac, renal, pulmonary,
             gastrointestinal, hematologic or hepatic conditions; or a condition that affects the
             absorption, distribution, metabolism or excretion of drugs

          -  Have elevated ALT (SGPT) or AST (SGOT) greater than 3 times upper limits of normal,
             or total bilirubin greater than 1.5 time ULN

          -  Have a history of malignancy within the past 2 years, with the exception of basal
             cell carcinoma

          -  Are currently following or planning to follow a ketogenic diet

          -  Use of dietary supplements or herbal preparations are not permitted if subject has
             been using them consistently for less than 6 months prior to screening, or does not
             plan on remaining on stable doses for the duration of the double blind phase. Use of
             St. John's Wort is not permitted

          -  Females who are pregnant, currently breastfeeding or planning to become pregnant
             during the duration of the study

          -  A history of chronic noncompliance with drug regimens

          -  Inability to withhold grapefruit and grapefruit juice from diet during the entire
             clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albena Patroneva, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Tsai, Ph.D.</last_name>
    <phone>203-315-5820</phone>
    <email>jtsai@marinuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Epilepsy Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3280</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl R Hall, CCRC</last_name>
      <phone>205-934-1654</phone>
      <email>Chall@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer DeWolfe, MD</last_name>
      <phone>205-934-1654</phone>
    </contact_backup>
    <investigator>
      <last_name>Jennifer DeWolfe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center, Inc</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Escamilla</last_name>
      <phone>559-437-9700</phone>
      <email>neurophillip@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Perminder Bhatia, MD</last_name>
      <phone>559-437-9700</phone>
    </contact_backup>
    <investigator>
      <last_name>Perminder Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Espinosa</last_name>
      <phone>310-315-1456</phone>
      <email>eespinosa@drkudrow.com</email>
    </contact>
    <contact_backup>
      <last_name>Jaime Latorre</last_name>
      <phone>310-315-1456</phone>
      <email>jlatorre@drkudrow.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Kudrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado- Anschutz Outpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Lervik</last_name>
      <phone>303-724-7309</phone>
      <email>kristen.lervik@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Strom, MD</last_name>
      <phone>303.724.7309</phone>
    </contact_backup>
    <investigator>
      <last_name>Laura Strom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medsol Clinical Research Center</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Vasconcelos</last_name>
      <phone>941-623-9744</phone>
      <email>mvasconcelos@medsolcrc.com</email>
    </contact>
    <contact_backup>
      <last_name>Susan Coldiron</last_name>
      <phone>941-623-9744</phone>
      <email>scoldiron@medsolcrc.com</email>
    </contact_backup>
    <investigator>
      <last_name>George Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bluegrass Epilepsy Research, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Clark</last_name>
      <phone>859-313-4273</phone>
      <email>bgepilepsy@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Toufic Fakhoury, MD</last_name>
      <phone>859.313.4273</phone>
      <email>bgepilepsy@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Toufic Fakhoury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Epilepsy Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkady Barber</last_name>
      <phone>301-530-9744</phone>
      <email>barbera@epilepsydc.com</email>
    </contact>
    <contact_backup>
      <last_name>Lenka Goldman</last_name>
      <phone>301-530-9744</phone>
    </contact_backup>
    <investigator>
      <last_name>Pavel Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Potretzke</last_name>
      <phone>763-302-4135</phone>
    </contact>
    <investigator>
      <last_name>Joanne Rogin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Comprehensive Epilepsy Care Center for Children and Adults</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Schaefer</last_name>
      <phone>314-453-9300</phone>
      <email>werosenfeld@msn.com</email>
    </contact>
    <investigator>
      <last_name>William Rosenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper Medical Center of Rowan University</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Lee</last_name>
      <phone>856-968-7222</phone>
      <email>Lee-tamara@cooperhealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cory Hackmyer</last_name>
      <phone>856-342-2460</phone>
      <email>Hackmyer-Cory@CooperHealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Evren Burakgazi-Dalkilic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Regional Epilepsy Group</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munazza Malik, MD</last_name>
      <phone>201-343-6676</phone>
      <phone_ext>122</phone_ext>
      <email>mmalik@epilepsygroup.com</email>
    </contact>
    <contact_backup>
      <last_name>Evan Fertig, M.D.</last_name>
      <phone>201-343-6676</phone>
    </contact_backup>
    <investigator>
      <last_name>Evan Fertig, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Brynes</last_name>
      <phone>516-663-2815</phone>
      <email>kbyrnes@winthrop.org</email>
    </contact>
    <investigator>
      <last_name>Shicong Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Comprehensive Epilepsy Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Tenzigolski</last_name>
      <phone>646-558-0842</phone>
      <email>Stephanie.Tenzigolski@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Hopkins</last_name>
      <email>maria.hopkins@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Blanca Vazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research Partners, LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Simpkins-Krec</last_name>
      <phone>330-494-2097</phone>
      <phone_ext>138</phone_ext>
      <email>JKrec@SSandG.com</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Shaffer</last_name>
      <phone>330-494-2097</phone>
      <phone_ext>138</phone_ext>
      <email>WShaffer@SSandG.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Drake, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Scarberry, RN</last_name>
      <phone>614-688-4678</phone>
      <email>Stephanie.Scarberry@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bassel Shneker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynn Health Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Freyman</last_name>
      <phone>405-602-3928</phone>
      <email>afreyman@lhsi.net</email>
    </contact>
    <contact_backup>
      <last_name>Phyllis Fahrenbruch</last_name>
      <phone>405-602-3939</phone>
      <email>pmorris@lhsi.net</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson Comprehensive Epilepsy Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Hewitt</last_name>
      <phone>215-503-3166</phone>
      <email>Gillian.Hewitt@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pranoti Pradhan</last_name>
      <phone>215-955-2245</phone>
      <email>Pranoti.Pradhan@Jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Sperling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Augelli</last_name>
      <phone>215-707-7310</phone>
      <email>brian.augelli@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Mercedes Jacobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Epilepsy Group</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Gonzales</last_name>
      <phone>972-707-8378</phone>
      <email>sgonzales@texasepilepsy.org</email>
    </contact>
    <contact_backup>
      <phone>972-707-8378</phone>
      <email>tsneed@texasepilepsy.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jay Harvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Burton, RN</last_name>
      <phone>425-251-1720</phone>
      <email>cdburton@rainier-research.com</email>
    </contact>
    <investigator>
      <last_name>David Vossler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 4, 2015</lastchanged_date>
  <firstreceived_date>October 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>partial onset seizures</keyword>
  <keyword>complex partial seizures</keyword>
  <keyword>simple partial seizures</keyword>
  <keyword>anticonvulsant</keyword>
  <keyword>ganaxolone</keyword>
  <keyword>neurosteroid</keyword>
  <keyword>Marinus</keyword>
  <keyword>epilepsy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
